摘要
目的探讨原发上皮性卵巢癌组织中DNA-PKcs和ERCC1表达与卵巢癌预后的关系。方法采用免疫组化SP法检测99例上皮性卵巢癌和16例正常卵巢组织中DNA-PKcs和ERCC1的表达。结果 DNA-PKcs和ERCC1在卵巢癌组织中的阳性率分别为60.61%和53.54%,均显著高于正常卵巢组织(P<0.01);DNA-PKcs和ERCC1表达呈显著正相关(r=0.408,P=0.000)。单因素分析显示,DNA-PKcs与ER-CC1共表达,FIGO分期、淋巴结转移、CA125半衰期、残留灶直径均与卵巢癌患者的生存时间有关(P<0.05)。多因素分析显示,ERCC1表达、FIGO分期、淋巴结转移与残留灶直径均是影响卵巢癌预后的独立危险因素。结论 DNA-PKcs和ERCC1在上皮性卵巢癌组织中表达率明显高于正常卵巢组织;联合检测DNA-PKcs与ERCC1表达可作为早期诊断及预测卵巢癌预后的指标。
Objective To explore the relationship of the expression of DNA-PKes and ERCC1 in primary ep- ithelial ovarian cancer with the prognosis ovarian cancer. Methods Expressions of DNA-PKes and ERCC1 were de-tected in 99 samples of epithelial ovarian cancer tissues, 16 samples of normal ovary tissues by immunohistochemical SP method. Results The positive rates of DNA-Pkcs and ERCC1 expression in epithelial ovarian cancer patients were 60. 61% （60/99） and 53.54% （53/99） respectively, the positive rates of DNA-PKcs and ERCC1 in epithelial ovari- an cancer tissues were apparently highter than normal ovary tissues（P 〈0.01 ） ; The expressions between DNA-PKcs and ERCC1 showed positive correlation（r = 0. 408, P = 0. 000） ; Single factor Kaplan-Meier analysis showed that the expressions of DNA-PKcs and ERCC1, the co-expression of DNA-Pkcs and ERCC1, the FIGO stage, lymph node metastasis, the half-life of serum CA125 and the diameter of residual tumor were correlated with the average survival time in ovarian cancer patients（P 〈 0. 05）. The expression of ERCC1, FIGO stage, lymph node metastasis and the diameter of residual tumor were related to the independent risk factors of ovarian cancer prognosis revealed by Cox multiple factors survival analysis. Conclusion The positive expression rates of DNA-Pkcs and ERCC1 in epithelial o- varian cancer patients were significantly higher than that in normal ovarian tissues; The combined detection of DNA- PKcs and ERCC1 in epithelial ovarian cancer patients is maybe a new target for early diagnosis and prediction of out- come for this disease.
出处
《中国临床新医学》
2013年第6期519-523,共5页
CHINESE JOURNAL OF NEW CLINICAL MEDICINE
基金
唐山市科技局科技攻关计划应用项目(编号:121302109a)
